Enavate Sciences, a company that invests in the growth of therapeutic and technology companies backed by Patient Square Capital, has added Edward Fleming Jr. as executive vice president of commercialization.

Fleming will augment Enavate’s capabilities in the origination, due diligence and negotiation of investment opportunities and support of Enavate partner companies with a focus on clinical development and commercial assessment at the product and portfolio levels. He was a senior partner at McKinsey and Co., where he was a leader in its life science practice. He was the leader of McKinsey’s research and development (R&D) practice for the past 8 years, leading the firm’s efforts in client service to R&D organizations and R&D knowledge development.

“I am pleased to welcome Edd to Enavate Sciences and look forward to his leadership as we execute our strategy to be a partner of choice for innovative biotech companies that strive to transform patient care and improve quality of life,” comments James Boylan, chief executive officer of Enavate Sciences. “Edd brings a wealth of relationships, experience, and judgment to Enavate Sciences that will greatly benefit our partner companies as they build their businesses through capital formation, clinical development, commercialization, and strategic considerations.”